In this issue:
Tenofovir for reducing perinatal HBV transmission
TAF vs TDF: long-term renal and bone safety data
PEG-IFN-α-2a: durable responses in HBeAg+ patients
DAA eradication of recurrent HCV infection improves metabolic profile
NGM282 looks promising in NASH
Glecaprevir/pibrentasvir in HCVinfected transplant recipients
SVR post-LT induces fibrosis regression
Let clinical pharmacist specialists manage DAAs for HCV?
Viekira Pak ± RBV for 8 weeks: effective in recent HCV infection
High SVR12 with glecaprevir/pibrentasvir (8 or 12 weeks) in HCV
Please login below to download this issue (PDF)